| Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. | |
| | |
MedLine Citation:
|
PMID: 20118387 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate the effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol (HDL-C) levels in atorvastatin-treated patients with elevated non-HDL-C and triglyceride levels. PATIENTS AND METHODS: This study, conducted between February 15, 2007, and October 22, 2007, randomized patients with elevated non-HDL-C (>160 mg/dL) and triglyceride (>or=250 mg/dL and <or=599 mg/dL) levels to double-blind treatment with prescription omega-3-acid ethyl esters, 4 g/d, or placebo for 16 weeks. Patients also received escalating dosages of open-label atorvastatin (weeks 0-8, 10 mg/d; weeks 9-12, 20 mg/d; weeks 13-16, 40 mg/d). RESULTS: Prescription omega-3-acid ethyl esters plus atorvastatin, 10, 20, and 40 mg/d, reduced median non-HDL-C levels by 40.2% vs 33.7% (P<.001), 46.9% vs 39.0% (P<.001), and 50.4% vs 46.3% (P<.001) compared with placebo plus the same doses of atorvastatin at the end of 8, 12, and 16 weeks, respectively. Prescription omega-3-acid ethyl esters plus atorvastatin also reduced median total cholesterol, triglyceride, and very low-density lipoprotein cholesterol levels and increased HDL-C levels to a significantly greater extent than placebo plus atorvastatin. Percent changes from baseline low-density lipoprotein-cholesterol, apolipoprotein A-I, and apolipoprotein B levels were not significantly different between groups at the end of the study. CONCLUSION: Prescription omega-3-acid ethyl esters plus atorvastatin produced significant improvements in non-HDL-C and other lipid parameters in patients with elevated non-HDL-C and triglyceride levels. |
| | |
Authors:
|
Harold E Bays; James McKenney; Kevin C Maki; Ralph T Doyle; Roderick N Carter; Evan Stein |
Related Documents
:
|
6797787 - Lipoprotein patterns in women in santo domingo using a levonorgestrel/estradiol contrac... 20682487 - Changes in the lipid profile of blood serum in women taking sauna baths of various dura... 19405827 - The relationship between serum lipids and periodontitis in elderly non-smokers. 8302497 - New recommendations for the diagnosis and treatment of plasma lipid abnormalities. 19409927 - Ghrelin - defender of fat. 8263467 - Development of collared lemmings, dicrostonyx groenlandicus, is influenced by pre- and ... |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Mayo Clinic proceedings. Mayo Clinic Volume: 85 ISSN: 1942-5546 ISO Abbreviation: Mayo Clin. Proc. Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-02-01 Completed Date: 2010-02-25 Revised Date: 2010-09-28 |
Medline Journal Info:
|
Nlm Unique ID: 0405543 Medline TA: Mayo Clin Proc Country: United States |
Other Details:
|
Languages: eng Pagination: 122-8 Citation Subset: AIM; IM |
Affiliation:
|
Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Ave, Louisville, KY 40213, USA. hbaysmd@aol.com |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00435045 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Analysis of Variance Cholesterol, HDL / blood, drug effects Cholesterol, LDL / blood, drug effects* Docosahexaenoic Acids / administration & dosage*, pharmacology Dose-Response Relationship, Drug Double-Blind Method Drug Combinations Drug Prescriptions Drug Therapy, Combination Eicosapentaenoic Acid / administration & dosage*, pharmacology Female Heptanoic Acids / administration & dosage*, pharmacology Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*, pharmacology Hypercholesterolemia / blood, complications, drug therapy* Hypertriglyceridemia / blood, complications, drug therapy* Male Middle Aged Pyrroles / administration & dosage*, pharmacology Treatment Outcome United States |
| Chemical | |
Reg. No./Substance:
|
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Drug Combinations; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Omacor; 0/Pyrroles; 110862-48-1/atorvastatin; 1553-41-9/Eicosapentaenoic Acid; 25167-62-8/Docosahexaenoic Acids |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Obesity paradox and cardiorespiratory fitness in 12,417 male veterans aged 40 to 70 years.
Next Document: Clinical, etiologic, and histopathologic features of stevens-johnson syndrome during an 8-year perio...